Generic Name and Formulations:
Cycloserine 250mg; caps.
Lilly, Eli and Company
Indications for SEROMYCIN:
In conjunction with other chemotherapy, for the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible and when treatment with primary drugs (streptomycin, isoniazid, rifampin, ethambutol) has proved inadequate.
Initially 250mg twice daily at 12-hour intervals for the first 2 weeks. Usual dose: 500mg–1g daily in divided doses monitored by blood levels. Max 1g/day.
Epilepsy. Depression. Severe anxiety. Psychosis. Severe renal insufficiency. Excessive concurrent use of alcohol.
Discontinue or reduce dose if allergic dermatitis or CNS toxicity develops. Ratio of toxic dose to effective dose is small. Monitor blood levels, hematologic, renal, and liver function. Obtain weekly blood levels in patients with reduced renal function, patients receiving >500mg daily dosage, or those showing signs/symptoms suggestive of toxicity. Pregnancy (Cat.C). Nursing mothers: not recommended.
Neurotoxic effects with concomitant ethionamide. Increased risk of epileptic episodes with alcohol. Increased CNS effects with concomitant isoniazid; monitor closely.
CNS effects (eg, convulsions, drowsiness, somnolence, headache, tremor, dysarthria, vertigo, confusion, psychoses, character changes, hyperirritability, aggression, paresis, hyperreflexia, paresthesia, seizures, coma), CHF, allergy, rash, elevated serum transaminase (esp. with preexisting liver disease), anemia (monitor).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline